By Fineline Cube 
Abbott (NYSE: ABT) reported global sales of USD 11.14 billion for the second quarter of 2025 (Q2 2025), representing a 6.9% year-on-year (YOY) growth in constant currency terms. Sales for the first half of 2025 (H1 2025) also increased by 6.9% to USD 21.5 billion. Abbott projects full-year 2025 organic sales growth between 6.0% and 7.0%.
Business Unit Performance
- Medical Devices: Sales rose by 12.2% to USD 5.37 billion, driven by diabetes care (particularly glucose monitors), heart failure, structural heart, electrophysiology, and cardiac rhythm management.
- Pharmaceuticals: Sales increased by 7.7% to USD 1.38 billion.
- Diagnostics: Sales decreased by 1.2% to USD 2.17 billion. The decline was attributed to reduced COVID testing sales and the impact of volume-based procurement programs in China.
- Nutrition: Sales grew by 3.4% to USD 2.21 billion.
Diagnostics Segment Insights
The 1.2% decrease in diagnostics sales was explained by CEO Robert B. Ford as due to the year-over-year decline in COVID testing sales and the effects of volume-based procurement programs in China. While the global Core Laboratory Diagnostics business saw a 1.6% sales increase, the expected volume sales improvement in China did not occur during Q2. Excluding China, the global core laboratory diagnostics business grew by 8% YOY.-Fineline Info & Tech